In a welcome move, Smith & Nephew ADR saw its Relative Strength Rating rise from 63 to 74 on Friday.
Can You Really Time The Stock Market?
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves. See if Smith & Nephew ADR can continue to show renewed price strength and clear that threshold.
Smith & Nephew ADR is working on a consolidation with a 31.72 buy point. See if it can clear the breakout price in heavy volume.
Smith & Nephew ADR posted -2% earnings growth in its most recent report. Revenue increased 6%.
Smith & Nephew ADR holds the No. 20 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and TransMedics Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
